ReviewExpert review of molecular diagnostics2014
Tissue slide-based microRNA characterization of tumors: how detailed could diagnosis become for cancer medicine?
Review in Expert review of molecular diagnostics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations.Oncotarget · 2016Pooled it
- Viral Encoded miRNAs in Tumorigenesis: Theranostic Opportunities in Precision Oncology.Microorganisms · 2022Review
- microRNA-based diagnostic and therapeutic applications in cancer medicine.Wiley interdisciplinary reviews. RNA · 2021Review
- Microfluidic circulating reactor system for sensitive and automated duplex-specific nuclease-mediated microRNA detection.Talanta · 2021Article
- Rapid and Sensitive Detection of miRNA Based on AC Electrokinetic Capacitive Sensing for Point-of-Care Applications.Sensors (Basel, Switzerland) · 2021Article
- Automated Five-Color Multiplex Co-detection of MicroRNA and Protein Expression in Fixed Tissue Specimens.Methods in molecular biology (Clifton, N.J.) · 2020Article
- Spatially resolved and multiplexed MicroRNA quantification from tissue using nanoliter well arrays.Microsystems & nanoengineering · 2020Article
- MiR-194 promotes hepatocellular carcinoma through negative regulation of CADM1.International journal of clinical and experimental pathology · 2020Article
- Implication of viral microRNAs in the genesis and diagnosis of Epstein-Barr virus-associated tumors.Oncology letters · 2019Review
- MicroRNA amplification and detection technologies: opportunities and challenges for point of care diagnostics.Laboratory investigation; a journal of technical methods and pathology · 2019Review
- miR-21 expression analysis in budding colon cancer cells by confocal slide scanning microscopy.Clinical & experimental metastasis · 2018Article
- Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway.Journal of translational medicine · 2016Article
- Positive expression of miR-361-5p indicates better prognosis for breast cancer patients.Journal of thoracic disease · 2016Article
- The miR-143/miR-145 cluster and the tumor microenvironment: unexpected roles.Genome medicine · 2016Article
- Critical analysis of the potential for microRNA biomarkers in breast cancer management.Breast cancer (Dove Medical Press) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
miRNAs are short, non-coding, regulatory RNAs that exert cell type-dependent, context-dependent, transcriptome-wide gene expression control under physiological and pathological conditions. Tissue slide-based assays provide qualitative (tumor compartment) and semi-quantitative (expression levels) information about altered miRNA expression at single-cell resolution in clinical tumor specimens. Reviewed here are key technological advances in the last 5 years that have led to implementation of fully automated, robust and reproducible tissue slide-based assays for in situ miRNA detection on US FDA-approved instruments; recent tissue slide-based discovery studies that suggest potential clinical applications of specific miRNAs in cancer medicine are highlighted; and the challenges in bringing tissue slide-based miRNA assays into the clinic are discussed, including clinical validation, biomarker performance, biomarker space and integration with other biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.